Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 16/20 | 0.49 |
| ▸ | PDE4A | P27815 | 14/20 | 0.49 |
| ▸ | PDE4C | Q08493 | 14/20 | 0.49 |
| ▸ | PDE4D | Q08499 | 14/20 | 0.49 |
| ▸ | HTR1A | P08908 | 4/20 | 0.41 |
| ▸ | HTR2B | P41595 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6878255 | 0.87 | PDE4B (0.52) | PDE4BPDE4APDE4CPDE4DHTR2B | |
| SCHEMBL5557255 | 0.86 | PDE4B (0.53) | PDE4BPDE4APDE4CPDE4DHTR2B | |
| SCHEMBL10325021 | 0.82 | PDE4B (0.54) | PDE4BPDE4APDE4CPDE4DHTR2B | |
| SCHEMBL5035837 | 0.81 | PDE4B (0.49) | PDE4BPDE4APDE4CPDE4DHTR2B | |
| SCHEMBL1193434 | 0.81 | PDE4B (0.76) | PDE4BPDE4APDE4CPDE4DHTR2B | |
| SCHEMBL6025567 | 0.80 | PDE4B (0.64) | PDE4BPDE4APDE4CPDE4DHTR2B | |
| SCHEMBL825879 | 0.80 | PDE4B (0.53) | PDE4BPDE4APDE4CPDE4DHTR2B | |
| SCHEMBL1583109 | 0.79 | PDE4B (0.66) | PDE4BPDE4APDE4CPDE4DHTR2B | |
| SCHEMBL10325442 | 0.79 | PDE4B (0.52) | PDE4BPDE4APDE4CPDE4DHTR2B | |
| SCHEMBL6876805 | 0.79 | PDE4B (0.49) | PDE4BPDE4APDE4CPDE4DHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1569903-A4 | METHODS OF USING AND COMPOSITIONS COMPRISING SELECTIVE CYTOKINE INHIBITORY DRUGS FOR THE TREATMENT AND MANAGEMENT OF MYELOPROLIFERATIVE DISEASES | CELGENE CORP (US) | 2009-07-29 | — | — | EP | disclosed |
| EP-1556033-A4 | METHODS AND COMPOSITIONS USING SELECTIVE CYTOKINE INHIBITORY DRUGS FOR TREATMENT AND MANAGEMENT OF CANCERS AND OTHER DISEASES | CELGENE CORP (US) | 2006-05-31 | — | — | EP | disclosed |
| EP-1569903-A2 | METHODS OF USING AND COMPOSITIONS COMPRISING SELECTIVE CYTOKINE INHIBITORY DRUGS FOR THE TREATMENT AND MANAGEMENT OF MYELOPROLIFERATIVE DISEASES | CELGENE CORPORATION (US) | 2005-09-07 | — | — | EP | disclosed |
| EP-1556033-A1 | METHODS AND COMPOSITIONS USING SELECTIVE CYTOKINE INHIBITORY DRUGS FOR TREATMENT AND MANAGEMENT OF CANCERS AND OTHER DISEASES | CELGENE CORPORATION (US) | 2005-07-27 | — | — | EP | disclosed |
| EP-1126839-A4 | SUBSTITUTED PHENETHYLSULFONES AND METHOD OF REDUCING TNF ALPHA LEVELS | CELGENE CORP (US) | 2004-10-27 | — | — | EP | disclosed |
| WO-2004043336-A2 | METHODS OF USING AND COMPOSITIONS COMPRISING SELECTIVE CYTOKINE INHIBITORY DRUGS FOR THE TREATMENT AND MANAGEMENT OF MYELOPROLIFERATIVE DISEASES | CELGENE CORPORATION (US) | 2004-05-27 | — | — | WO | disclosed |
| WO-2003097040-A1 | METHODS AND COMPOSITIONS USING SELECTIVE CYTOKINE INHIBITORY DRUGS FOR TREATMENT AND MANAGEMENT OF CANCERS AND OTHER DISEASES | CELGENE CORPORATION (US) | 2003-11-27 | — | — | WO | disclosed |
| EP-1126839-A1 | SUBSTITUTED PHENETHYLSULFONES AND METHOD OF REDUCING TNF ALPHA LEVELS | CELGENE CORPORATION (US) | 2001-08-29 | — | — | EP | disclosed |
| WO-2000025777-A1 | SUBSTITUTED PHENETHYLSULFONES AND METHOD OF REDUCING TNFαLEVELS | CELGENE CORPORATION (US) | 2000-05-11 | — | — | WO | disclosed |